Literature DB >> 29101731

miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2.

Guopeng Xu1, Zhongwei Zhang1, Li Zhang2, Ying Chen1, Ning Li1, Yantian Lv1, Yong Li1, Xiao Xu3.   

Abstract

microRNAs have been reported to play vital role in lung cancer proliferation and metastasis; the role of miR-4326 in tumor progression has not been studied. Here, we studied the effect of miR-4326 on lung cancer cell proliferation; we found that miR-4326 was significantly upregulated in lung cancer tissues determined using TCGA dataset and clinical specimens, meanwhile it was also upregulated in lung cancer cells. Overexpression of miR-4326 promoted lung cancer cell proliferation analyzed by MTT, soft agar growth, and BrdU incorporation assay, while miR-4326 knockdown suppressed lung cancer cell proliferation. We found miR-4326 targets tumor suppressor adenomatous polyposis coli 2 (APC2), which is a negative regulator of Wnt pathway, by binding to the 3'UTR of APC2. Wnt pathway could increase Cyclin D1 and c-MYC expression, we also found that miR-4326 could increase their expression, suggesting that APC2 was the target of miR-4326. Moreover, double knockdown of APC2 and miR-4326 promoted lung cancer cell proliferation, confirming that miR-4326 promoted lung cancer cell proliferation by inhibiting APC2.

Entities:  

Keywords:  APC2; Lung cancer; Proliferation; miR-4326

Mesh:

Substances:

Year:  2017        PMID: 29101731     DOI: 10.1007/s11010-017-3219-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  19 in total

1.  Crizotinib.

Authors:  Alice T Shaw; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

2.  Testing hypotheses for the functions of APC family proteins using null and truncation alleles in Drosophila.

Authors:  Brooke M McCartney; Meredith H Price; Rebecca L Webb; Melissa A Hayden; Lesley M Holot; Mengning Zhou; Amy Bejsovec; Mark Peifer
Journal:  Development       Date:  2006-06       Impact factor: 6.868

Review 3.  New advances of TMEM88 in cancer initiation and progression, with special emphasis on Wnt signaling pathway.

Authors:  Yun-Xuan Ge; Chang-Hui Wang; Fu-Yong Hu; Lin-Xin Pan; Jie Min; Kai-Yuan Niu; Lei Zhang; Jun Li; Tao Xu
Journal:  J Cell Physiol       Date:  2017-04-27       Impact factor: 6.384

4.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 5.  The β-catenin destruction complex.

Authors:  Jennifer L Stamos; William I Weis
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

6.  miR-937 contributes to the lung cancer cell proliferation by targeting INPP4B.

Authors:  Li Zhang; Daxiong Zeng; Ying Chen; Ning Li; Yantian Lv; Yong Li; Xiao Xu; Guopeng Xu
Journal:  Life Sci       Date:  2016-05-12       Impact factor: 5.037

7.  The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.

Authors:  Heather E Croy; Caitlyn N Fuller; Jemma Giannotti; Paige Robinson; Andrew V A Foley; Robert J Yamulla; Sean Cosgriff; Bradford D Greaves; Ryan A von Kleeck; Hyun Hyung An; Catherine M Powers; Julie K Tran; Aaron M Tocker; Kimberly D Jacob; Beckley K Davis; David M Roberts
Journal:  J Biol Chem       Date:  2016-04-11       Impact factor: 5.157

8.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

9.  miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer.

Authors:  Dong Yang; Ming Zhan; Tao Chen; Wei Chen; Yunhe Zhang; Sunwang Xu; Jinchun Yan; Qihong Huang; Jian Wang
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

10.  miR-494-3p is a novel tumor driver of lung carcinogenesis.

Authors:  Alice Faversani; Stefano Amatori; Claudia Augello; Federico Colombo; Laura Porretti; Mirco Fanelli; Stefano Ferrero; Alessandro Palleschi; Pier Giuseppe Pelicci; Elena Belloni; Giulia Ercoli; Anna Degrassi; Marco Baccarin; Dario C Altieri; Valentina Vaira; Silvano Bosari
Journal:  Oncotarget       Date:  2017-01-31
View more
  7 in total

1.  The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma.

Authors:  Yanxia Jiang; Yajing Luan; Hong Chang; Guoan Chen
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

2.  LINC01578 affects the radiation resistance of lung cancer cells through regulating microRNA-216b-5p/TBL1XR1 axis.

Authors:  Peirong Wang; Linchun Ke; Chuanshu Cai; Feng Dong
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  The MicroRNA hsa-let-7g Promotes Proliferation and Inhibits Apoptosis in Lung Cancer by Targeting HOXB1.

Authors:  Fenghe Cui; Qian Zhou; Kuang Xiao; Shengwei Ma
Journal:  Yonsei Med J       Date:  2020-03       Impact factor: 2.759

4.  miRNAs Contained in Extracellular Vesicles Cargo Contribute to the Progression of Idiopathic Pulmonary Fibrosis: An In Vitro Aproach.

Authors:  Jovito Cesar Santos-Álvarez; Juan Manuel Velázquez-Enríquez; Rosendo García-Carrillo; César Rodríguez-Beas; Alma Aurora Ramírez-Hernández; Edilburga Reyes-Jiménez; Karina González-García; Armando López-Martínez; Laura Pérez-Campos Mayoral; Sergio Roberto Aguilar-Ruiz; María de Los Ángeles Romero-Tlalolini; Honorio Torres-Aguilar; Luis Castro-Sánchez; Jaime Arellanes-Robledo; Verónica Rocío Vásquez-Garzón; Rafael Baltiérrez-Hoyos
Journal:  Cells       Date:  2022-03-25       Impact factor: 6.600

5.  Identification of Six N7-Methylguanosine-Related miRNA Signatures to Predict the Overall Survival and Immune Landscape of Triple-Negative Breast Cancer through In Silico Analysis.

Authors:  Jing Xu; Xiaoxia Cen; Yu Yao; Suo Zhao; Wei Li; Wei Zhang; Ming Qiu
Journal:  J Oncol       Date:  2022-09-26       Impact factor: 4.501

6.  Low expression of adenomatous polyposis coli 2 correlates with aggressive features and poor prognosis in colorectal cancer.

Authors:  Yan Sun; Hua Tian; Xuehu Xu; Lin Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

7.  LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/β-Catenin Pathway.

Authors:  Sadia Mehdi; Magdalena Bachvarova; Marie-Pier Scott-Boyer; Arnaud Droit; Dimcho Bachvarov
Journal:  Int J Mol Sci       Date:  2020-03-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.